Castle biosciences reports first quarter 2025 results

Q 1 2025 revenue increased 21% over q 1 2024 to $88 million q 1 2025 total test reports for our core revenue drivers (decisiondx ® -melanoma, decisiondx ® -scc, tissuecypher ® ) increased 33% over q 1 2024 raising full-year 2025 revenue guidance to $287-297 million from $280-295 million conference call and webcast today at 4:30 p.m. et friendswood, texas, may 05, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended march 31, 2025.
CSTL Ratings Summary
CSTL Quant Ranking